Dana Farber Gets $33M from Sanofi, Astellas Backs DecImmune, Ironwood Sells Microbia, & More Boston-Area Deals News

9/29/10Follow @xconomy

(Page 2 of 2)

to $17 million.

—Harvest Automation, a Billerica, MA-based robotics company working on automating the harvesting of commercial plants, topped off its Series A round at $5.3 million, with a $1.3 million investment from Cambridge- and New York City-based Founder Collective. The startup brought in the first $4 million of the funding round in January of this year.

—Cambridge-based DecImmune Therapeutics, a developer of drugs for treating tissue damage, said it had raised $1 million in equity-based funding from Astellas Venture Management, the venture capital arm of Japanese drugmaker Astellas Pharma. The startup, formerly known as Natural Antibodies, also said it received $2.2 million in research grant money from the National Institutes of Health.

OnePIN, a Westborough, MA-based maker of mobile phone software for managing social contacts, raised $1.9 million of a potential $3.1 million equity-based funding round, an SEC filing showed. The company has previously received funding from FA Technology Ventures, Greycroft Partners, Egan-Managed Capital, and Stage 1 Technology Ventures.

—Marlborough, MA-based diagnostics company PointCare Technologies pulled in $1.8 million of an equity offering that could total $3.5 million, according to an SEC filing. The startup produces lower-cost, multi-purpose devices for targeting HIV/AIDS in developing countries.

—Andera, a Providence, RI-based maker of Web-based software for banks and other institutions offering online account opening and funding to consumers, said it had wrapped up a $9 million financing, led by Edison Venture Fund. The money will go to expanding Andera’s sales, marketing, and product development efforts.

—An SEC filing showed that Mechanology, an Attleboro, MA-based developer of compressor technology, raised $5.8 million in an equity round that could total $6.5 million.

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.